One-year programme in clinical trial management

August 26, 2011 02:42 pm | Updated 02:48 pm IST - TIRUCHI:

K. Anbarasu, right, Principal, National College, and P. Anandhapadmanabhan, Managing Director, Consortium Clinical Research Pvt. Ltd. Coimbatore, exchanging MoU in Tiruchi on Thursday. Photo: R. Ashok.

K. Anbarasu, right, Principal, National College, and P. Anandhapadmanabhan, Managing Director, Consortium Clinical Research Pvt. Ltd. Coimbatore, exchanging MoU in Tiruchi on Thursday. Photo: R. Ashok.

The National College (Autonomous) on Thursday signed a Memorandum of Understanding with Coimbatore-based Consortium Clinical Research Pvt. Ltd., to offer a postgraduate diploma in ‘Clinical Trial Management and Regulatory Affairs' for students of pharma, paramedical and life sciences.

The one-year programme to be conducted on week-ends includes practical and on-job training in real-time projects. The highlight of the programme, which is open for students from other institutions in and around Tiruchi, is that candidates with potential will be absorbed into industry, the college assures.

At a function organised on Thursday to mark the signing of MoU, Nagalakshmi Anandapadmanabhan, Chief Executive Officer of the Consortium, delivered key note address on ‘Ethics in Biomedical Research'.

College Principal K. Anbarasu and P. Anandapadmanaban, Managing Director of the Consortium, exchanged the MoU documents in the presence of Chandra Kumar, Managing Director, Kavery Medical Centre and Hospitals, Tiruchi; and K. Ragunathan, College Secretary.

According to M.N. Abubacker, Head, Department of Biotechnology, National College, career orientation is vital for students who must know ethical issues and regulatory framework as well alongside technology.

The global Clinical Resource Outsourcing market was worth 20 billion US $ in 2008 with a year on year growth rate of 20 per cent. The market includes services provided to pharma and biotech companies in the clinical development process for innovative molecules as well as generics.

A robust pipeline of patent expires in the near future, and a potential progress in authorized generic efforts and technology-enhanced generics were expected to drive the growth. This year, the more than 15 per cent of the total global clinical trials will be conducted in India, he said.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.